

**Transparency of Financial Support to Patient Organisations
And Engagements of Patient Organisations
Disclosures for Calendar Year 2025**

Czech Republic

Description of Financial Support from Tillotts Pharma Czech s.r.o	Value
Pacienti IBD z.s., Prague The donation is provided to cover the costs associated with Svatováclavské IBD konference.	CZK 40'000

Spain

Description of Financial Support from Tillotts Pharma Iberia	Value
ACCU - Confederación de Asociaciones de Enfermos de Crohn y Colitis Ulcerosa de España, Madrid : World IBD Day Sponsorship	EUR 3'000

Portugal

Description of Financial Support from Tillotts Pharma Portugal	Value
APDI - Associação Portuguesa Doença Inflamatória do Intestino, Colite Ulcerosa, Doença de Crohn de Portugal, Support for the Dialogues meeting in Viseu 28/06/25	EUR 1'000

Switzerland

Description of Financial Support from Tillotts Pharma AG	Value
Crohn Colitis Switzerland, Aarau: Support for Event Weinfeld, 2025	CHF 2'000

Methodological Notes

The methodological notes below explain the data Tillotts Pharma AG and its affiliates (“Tillotts”) have disclosed and how the data related to patient organisations and members of public have been prepared, to assist the reader’s understanding. In accordance with the EFPIA Code of Practice, pharmaceutical companies are required to publish a summary of the methodologies used in preparing disclosure data.

1. Disclosure by Tillotts of payments to patient organisations in 2025

The EFPIA Code of Practice requires the public disclosure of certain ToV made to patient organisations, according to Section 24 of the EFPIA Code of Practice. The relevant data for 2025 is published in 2026 on the Tillotts website (www.tillotts.com)

Basis of Disclosure

ToV to patient organisations are disclosed on a per organisation basis.

- Where multiple activities occur within a reporting period, these may be aggregated into a single annual total per organisation.
- Individual events, activities, or transactions are not itemised in the public disclosure.
- This approach is consistent with the EFPIA requirement to disclose total amounts per organisation together with a description of support.

Direct, Indirect, In-Kind and Cross-Border ToV

For the purposes of this report, the following definitions apply:

- *Direct ToV*: payments or other support provided directly by Tillotts to the benefiting organisation.
- *Indirect ToV*: payments or other support provided through an intermediary, acting on behalf of Tillotts, for the benefit of an organisation that can be clearly identified.
- *In-kind ToV*: non-monetary support provided to the benefiting organisation.
- *Cross-border ToV*: ToV made to an organisation registered in a country other than the country in which the Tillotts entity providing the funding is based. Where required by local law, such ToV are disclosed in the country in which the organisation is formally registered. Cross-border ToV made by Tillotts are included in this report unless local law provides otherwise. ToV to individual patients who do not represent, and are not engaged through, a patient organisation are not subject to disclosure. Examples may include payments to individual patients participating in market research or engaged to create content.

2. Description of Support

Each disclosure includes a description of the nature of support, designed to be sufficiently clear to enable the reader to understand the general purpose of the funding or services provided.

VAT

VAT is excluded from all disclosures of ToV.

Financial Aspects

Tillotts applies the following principles to determine the relevant payment date for each category of ToV:

- For Direct ToV, the payment date is the clearing date recorded through the banking system.
- For Indirect ToV related to events or for in-kind/non-financial support, the payment date is the last day of the relevant event.
- For Cross-border ToV, as defined above, the payment date is determined in line with the applicable category: for Direct ToV, the clearing date recorded through the banking system applies; for Indirect ToV, the last day of the relevant event applies.

All disclosures are made in local currency.

Data Protection

Tillotts Pharma complies with applicable data protection legislation.

For:

- Patient organisations – disclosures are made at organisational level
- Members of the public – disclosures are made in aggregated form

No personal data identifying individual members of the public is disclosed.

TILLOTTS UK LTD ABPI DISCLOSURE REQUIREMENTS ON TRANSFERS OF VALUE TO MEMBERS OF THE PUBLIC AND PATIENT ORGANISATION FOR FINANCIAL YEAR 2025

Members of the Public*:

Number of Members of the Public Contracted	Description of Financial Support from Tillotts Pharma UK Ltd	Transfer of Value type	Value (£)
1	Insights sessions, Travel & accommodation reimbursement	Fees	200
		Expenses	285.75
		Total	485.75

*Other Members of the Public including Caregivers, Patient Advocates, and Models etc

Patient organisation:

Name of Patient Organisation	Description of Financial Support from Tillotts Pharma UK Ltd	Value (£)
#GETYOURBELLYOUT	Grant, Event stand, Donation of electronic goods, Travel & accommodation reimbursement	5710.57
IBDrelief	Event stand, Travel & accommodation reimbursement	443.84
C. diff Trust	Conference sponsorship, Support the launch and day-to-day activities of the Trust	77500
	Total	83654.41

Methodological Notes

The methodological notes below explain the data Tillotts Pharma UK (“Tillotts”) have disclosed and how the data related to patient organisations and members of public have been prepared, to assist the reader’s understanding. In accordance with the ABPI Code of Practice, pharmaceutical companies are required to publish a summary of the methodologies used in preparing disclosure data.

1. Disclosure by Tillotts of payments to patient organisations in 2025

The ABPI Code of Practice requires the public disclosure of certain Transfers of Value (“ToV”) made to patient organisations, including donations, grants, sponsorship and contracted services (Clause 29). The relevant data for 2025 is published in 2026 on the Tillotts Pharma AG’s website (www.tillotts.com)

Basis of Disclosure

ToV to patient organisations are disclosed on a per organisation basis.

- Where multiple activities occur within a reporting period, these may be aggregated into a single annual total per organisation.
- Individual events, activities, or transactions are not itemised in the public disclosure.
- This approach is consistent with the ABPI requirement to disclose total amounts per organisation together with a description of support.

Description of Support

Each disclosure includes a description of the nature of support, designed to be sufficiently clear to enable the reader to understand the general purpose of the funding or services provided.

2. Disclosure by Tillotts of payments to public, including patients and journalists, in 2025

The ABPI Code of Practice requires disclosure of certain ToV made to members of the public, including patients and journalists (Clause 30). The relevant data for 2025 is published in 2026 on the Tillotts Pharma AG’s website (www.tillotts.com).

Basis of Disclosure

ToV to members of the public are disclosed on an aggregate basis only.

Each disclosure includes:

- The total number of individuals
- The total amount paid
- A high-level description of the types of services provided

Individual recipients are not identified, in line with ABPI requirements.

VAT

VAT is excluded from all disclosures of ToV.

Currency

All disclosures are made in Pounds Sterling (£). Where the original payment was made in another currency (for example Swiss Francs or Euros (€)), the sum was converted to pounds at the exchange



ZERIA GROUP

TILLOTTS PHARMA

rate prevailing at the time of the original payment or were converted to pounds at the average annual exchange rate of the European Central Bank for calendar year 2025.

Consolidated Disclosures of the Corporate Group and Cross border payments

The disclosures represent the consolidated ToV made by the Tillotts corporate group in line with the EFPIA Disclosure Code's dictate that separate entities belonging to the same multinational company (which could be the parent company and subsidiary company) shall be deemed to constitute a single company. The disclosures represent payments by Tillotts Pharma UK Ltd, Tillotts Pharma AG (of which Tillotts Pharma UK Ltd. is a wholly owned subsidiary), and other overseas affiliates. These methodology notes apply equally to the disclosures made by Tillotts Pharma AG and Tillotts Pharma UK Ltd.

Data Protection

Tillotts complies with applicable data protection legislation.

For:

- Patient organisations – disclosures are made at organisational level
- Members of the public – disclosures are made in aggregated form

No personal data identifying individual members of the public is disclosed.